At a glance

ClinicalIndex Comparison Record

N/ACompleted· 26 enrolled

Drug / intervention

Rituximabdrug

Likely dose

Rituximab 375 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00648037

NCT00648037N/ACompleted

Compare CT.gov

Pilot Trial of Rituximab (Rituxan) for the Prevention of EBV-LPD Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 1, 2008·Updated Feb 1, 2016

In Brief

A clinical study evaluating Rituximab for Hodgkin's Disease and 3 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if we can prevent Epstein Barr Virus lymphomas by the monthly administration of an (antibody) protein against B lymphocytes called Rituximab. Although this medicine has been approved by the Food and Drug Administration to treat patients with other types of lymphomas, and has been used to treat a small number of patients with EBV lymphomas and other types of B-cell leukemias, it has not been approved to try and prevent EBV-lymphomas. Use of Rituximab to try to prevent EBV-lymphomas is therefore experimental.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHodgkin's Disease, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma

CountriesUnited States

Collaborators--

Timeline

N/ACompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartMar 2008

First PostedApr 2008

Primary CompletionDec 2008

TodayJul 2026

First PostedApr 1, 2008

Enrollment StartMar 1, 2008

Primary CompletionDec 1, 2008

TodayJul 2, 2026

Enrollment to primary: 9 monthsPosted 18.3 years ago

Interventions

Rituximabdrug

Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.